Common adverse events associated with treatment of mantle cell lymphoma include gastrointestinal, hematologic, and cardiac toxicities. Proactive management of these toxicities and collaboration between members of the cancer care team, including pharmacists, are key to optimizing patient outcomes. In this episode, CANCER BUZZ speaks with Karen Fancher, PharmD, BCOP, clinical pharmacy specialist in oncology at University of Pittsburgh – Passavant Hospital, and Victoria Nachar, PharmD, BCOP, clinical pharmacist specialist in ambulatory hematology and adjunct clinical instructor at the University of Michigan, about strategies to address common adverse events experienced by patients with mantle cell lymphoma.

"There are some unique strategies using electronic resources if patients can be tech-savvy…We have some cool technology that use[s] text-message-based responses, where you can ask patients about side effects or vital signs. All they have to do is text a response, and it will automatically populate into the electronic medical record."—Victoria Nachar, PharmD, BCOP

"I'm at a very small community practice…Institutions like Michigan are light years ahead of some of us in terms of patient-friendly communication strategies through technology…As those institutions perfect and work out the kinks, [the technology] is going to trickle down to those of us in the community setting. And I'm really excited to see how we can harness that technology for patients."—Karen Fancher, PharmD, BCOP

Victoria Nachar, PharmD, BCOP

Clinical Pharmacist Specialist, Ambulatory Hematology

Adjunct Clinical Instructor

University of Michigan Rogel Cancer Center

Ann Arbor, MI

Karen Fancher, PharmD, BCOP Clinical Pharmacy Specialist, Oncology

University of Pittsburgh Medical Center – Passavant Hospital

Associate Professor of Pharmacy Practice Duquesne University School of Pharmacy Pittsburgh, PA

This video podcast was produced in partnership with The Leukemia & Lymphoma Society and made possible with support from Eli Lilly.

Resources

Cancer Diagnostics Education Program - ACCC

Treatment for Relapsed/Refractory Mantle Cell Lymphoma Tip Sheet - ACCC

BTK Inhibitors Stretch Frontline Approaches in Mantle Cell Lymphoma – Targeted Oncology

Emerging Data Continue to Affect BTK Inhibitor Usage in Mantle Cell Lymphoma - OncLive

HCP Fact Sheet: Facts About CAR T-cell Therapy

The CAR T-cell Therapy Process

Patient-Caregiver CAR T-cell Therapy Facts

Learn About CAR T-cell Therapy

Mantle Cell Lymphoma Facts for Patients and Caregivers -The Leukemia & Lymphoma Society